Methods: This was an observational, cross-sectional study of 243 male and female individuals between the ages of 12-26. The sample consists of participants in the Canadian Psychiatric Risk and Outcome Study (PROCAN) and included: asymptomatic participants at familial high risk for SMI (Stage 0; n=41); youth with early mood or anxiety symptoms (Stage 1a; n=52); youth with attenuated psychotic or affective syndromes and distress (Stages 1b; n=108); and HCs (n=42). The neurocognitive battery included the WRAT-4 reading task, WASI Vocabulary and WASI Matrix Reasoning tasks, and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). All neurocognitive tasks were administered at baseline. Group differences in neurocognitive performance were analyzed using MANCOVA/ANCOVA analyses. Covariates included age and sex. Results: Subjects in Stage 0 and Stage 1a did not significantly differ from any group. Subjects in Stage 1b (attenuated syndromes) had significantly lower neurocognitive scores in the domains of speed of processing, working memory, attention/vigilance and reasoning and problem solving, and on composite scores of neurocognitive performance and full-scale IQ compared to HCs. A secondary analysis demonstrated that subjects in Stage 1b who met CHR status according to Criteria of Psychosis-risk Syndromes (n=83) had lower scores in the domains of working memory, verbal learning, and reasoning and problem solving and on the overall composite score than the other participants in Stage 1b who did not meet CHR criteria. Discussion: This study provides evidence for a growing literature which suggests that neurocognitive deficits may be markers of susceptibility for SMI development. It also increases what is known about neurocognitive performance associated with different stages of risk for SMI. Identification of such impairments could aid with detection of early mental health problems prior to illness onset.
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Background: Previous literature comparing cognitive functioning between bipolar disorder (BD) and schizophrenia (Sch), particularly focused on remitted patients with BD (i.e. euthymics) and clinically stable patients with Sch; and suggested milder cognitive impairment in BD in comparison to Sch. Acute psychotic symptoms may lead poorer cognitive functioning in both disorders. Limited evidence suggests milder deficits in psychotic mania than in acute psychosis in Sch. We aimed to compare cognitive functioning in Sch and BD during the remission and the psychotic states. Methods: Several domains of cognitive functioning were compared among patients with BD who had a history of psychosis [32 with a current psychotic manic episode, 44 in euthymia for at least 6 months] and patients with Sch [41 with psychotic symptoms, 39 remitted according to Andreassen et al. criteria (2006) ] in comparison to 55 healthy controls (HC). Participants performed a cognitive battery including Wisconsin Card Sorting, Rey Auditory Verbal Learning, Stroop, Auditory Consonant Trigram, Trail Making, Digit Span, Controlled Word Association, Category Fluency and Digit Symbol tests. Principal components analyses were performed to extract the 'global cognition' factor and for dimensionality reduction to identify neurocognitive domains among patients with BD and Sch. The optimum number of cognitive components was identified by inspecting the scree plot. Each factor score was assessed for normality by calculating tests of skewness and kurtosis. The factor scores were compared between patients with Sch and patients with BD using two-way analyses of variance (ANCOVA) adjusting for age. Pairwise comparisons with Bonferroni corrections were used for post-hoc analysis. Background: About 85% of patients with schizophrenia have cognitive impairments, executive functions being particularly affected. Executive dysfunctions are important predictors of functional outcomes. Unlike psychotic symptoms, cognitive deficits do not improve during periods of remission and change only minimally with antipsychotic medications. Thus, effective interventions aimed at improving executive functions in this population are needed. One of the most validated interventions for executive dysfunction is Goal Management Training (GMT). GMT is a compensatory intervention that relies on metacognitive strategies for improving participants' ability to organize and achieve goals in everyday life. GMT has received empirical support in studies of other populations, such as people with neurological conditions and in healthy elderly. To our knowledge no previous studies have investigated the effect of group-based GMT in patients with schizophrenia spectrum disorders or with high risk of schizophrenia. Thus, this is the main objective of the study. Baseline characteristis and preliminary results from the first patients will be presented. Methods: Participants (16-67 years, males and females, IQ >70) with executive dysfunction, will be recruited among patients referred for treatment at Innlandet Hospital Trust in Norway from 2017 to 2020. The study aims to include patients treated for psychotic disorder for less than 5 years and new patients who either have symptoms that meet the DSM-IV criteria for a diagnosis of broad schizophrenia spectrum disorder or who are considered at high risk of psychosis. We aim to recruit one hundred participants for the current randomized controlled trial (RCT), with efficacy of GMT (n = 50) being compared with results of subjects in a wait-list condition (WL, n = 50). Measurements include self-report of executive function, emotional health, and social-and everyday function. Informant reports of executive function will also be collected. Furthermore, neuropsychological tests designed specifically to measure areas of executive function will be utilized, as well as role-playing tasks thought to have good ecological validity. Symptoms of psychosis will also be assessed. GMT will be administered in 9 (twice weekly) x 2 hour sessions in accordance with the GMT research protocol. A general linear model with repeated measures analysis of variance (RM ANOVA) will be used to examine differential group treatment effects. A 2 x 3 mixed-design will be applied, with Group (GMT, WL) as betweensubjects factor, and Session (baseline [T1], post-intervention [T2], and 6 months follow-up [T3]) as within-subjects factor. Interpretation of the strength of experimental effects will be provided with effect size statistics. Results: Baseline characteristics and preliminary results from the first participants will be presented. Discussion: Based on findings from previous GMT-studies, we hypothesize that post-intervention changes will be reflected in improved scores on selfreported and/or objective measures of executive functions (particularly in the areas of planning and attentional control) compared to patients in WL. We also expect that GMT participants will improve their goal attainment in everyday life and social functioning after the intervention. Additionally, we expect post-intervention changes to be reflected in improved scores on measures of emotional health. 
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Background: CoQ10 is a vital component of mitochondrial function and metabolism, and its deficiency creates greater vulnerability to disease due to impaired mitochondrial energy generation and cellular antioxidant capacity. CoQ10 functions as an electron carrier within the mitochondrial electron transport chain during cellular respiration. Schizophrenia is a disorder with documented CoQ10 deficiency and mitochondrial dysfunction, and cellular respiration and mitochondrial network dynamics can be impaired due to altered complex 1 activity in the disorder. Key features of schizophrenia such as depression, fatigue and cognitive impairment have been independently associated with mitochondrial dysfunction and increased oxidative stress. In bipolar disorder, fibromyalgia, chronic fatigue syndrome and multiple sclerosis these symptoms have been effectively reduced through CoQ10 supplementation. We assess the impact of CoQ10 supplementation in individuals with a diagnosis of schizophrenia through a double-blind, randomised, placebo-controlled study.
Methods: Approximately 300 participants with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder, with no neurological or psychiatric co-morbidity will be recruited to this study. Participants will be randomised to take 100 mg dose capsules of CoQ10 or placebo three times daily for six months, and undergo neuropsychological and cognitive testing at three time points (baseline, midpoint, six months post-randomisation). Changes in participants' global cognitive function, sustained attention, working memory, processing speed, negative symptoms, levels of depression and anxiety, fatigue, blood pressure, quality of life and functional status following CoQ10 supplementation will be assessed. Blood samples are also taken at each assessment session to assess baseline and changes in levels of plasma CoQ10 and mitochondrial function via lactate analysis. Results: Currently baseline data is available for 42 participants (mean age = 50.2, SD=10.7). All participants either have a clinical diagnosis of schizophrenia (n=34) or schizoaffective disorder (n=8). The mean estimated IQ of the group is 92.4 (SD=20.5), and participants have a median of 13 years in education. Thirty-nine percent of participants reported mild to severe levels of depression and twenty-three percent reported moderate or severe levels of anxiety. Seventy-three percent of participants reported good to very good quality of life. FACIT-fatigue scores were negatively correlated with both depression and anxiety scores, such that greater fatigue levels were associated with higher levels of depression (r=-.484, p<0.01) and anxiety (r=-.539, p<0.01). Discussion: CoQ10 is a mitochondrial agent that plays a fundamental role in energy production and mitochondrial function. The available baseline data suggest a relationship between fatigue and depression and anxiety levels in individuals with a diagnosis of schizophrenia. CoQ10 supplementation has the potential to affect these symptoms, through CoQ10's ability to restore electron flow in the electron transfer chain and increase mitochondrial antioxidant capacity. The study commenced in November 2016 and patient enrolment and assessment is ongoing. Updated baseline information will be presented including further cognitive assessments. To minimise risk of bias while recruitment and assessments are ongoing, unblinding and outcome analysis will not be conducted at time of presentation. Background: Resilience provides a new understanding of the highly variable trajectories of mental illness, and has consistently been linked with improved mental health outcomes. Resilience is largely defined as the presence of additional factors which overcome a specific risk for mental illness, leading to ultimately more positive outcomes than expected given said risk. Previous research in the area has focused on identifying psychological factors which may be associated with resilience. Moving forwards, it is essential that researchers investigate how resilience may function in different domains. The aim for the present research was to conduct a preliminary investigation into the possible role of neuropsychological performance in resilience using data from the PRONIA study. Methods: Participants were individuals aged 15-40 who were recruited into the PRONIA study. Total scores for the Resilience Scale for Adults (RSA), assessing self-report psychological resilience, were available for 587 participants. The sample included individuals with first-episode psychosis (N=113), first-episode depression (N=118), individuals at ultra-high risk for psychosis (N=109), and healthy controls (N=247). Participants also completed a comprehensive neuropsychological test battery which assessed performance in the following domains: IQ, executive functioning (EF), processing speed (PS), sustained attention, working memory, visual memory, social cognition, motivational salience, and verbal learning and memory. Results: A stepwise multiple linear regression was used to identify which of the neuropsychological domains would best predict RSA total score. The final model significantly predicted RSA total score, explaining 4% of the variance in these scores, F(2, 512) = 12.37, p < 0.001. The model indicated that higher RSA total was associated with PS (β=3.35, p=.032) and EF (β=4.15, p=0.046) . EF provided the highest relative contribution in the model, with every 1 point increase resulting in 4.15 standard deviation increase in RSA total. Discussion: The present results suggest that neuropsychological performance has a small, but significant relationship with psychological resilience. The two neuropsychological domains which best predicted this outcome were PS and EF. Resilience has been argued to be a highly dynamic process, by which individuals must utilise assets and resources to their benefit. Furthermore, the effectiveness of such factors will vary across time and circumstance, adding to the flexibility required to navigate this process. These results support this conceptualisation of resilience, as EF is thought to involve the organisation and execution of complex thoughts and behaviour. Processing speed has also been found to affect other cognitive functions
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